Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-SARS-CoV-2 intravenous immunoglobulin (UHS Lahore)
- Development stage
- Unknown
- Lead developer
- Sağlık Bilimleri Üniversitesi
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
anti-SARS-CoV-2 intravenous immunoglobulin (UHS Lahore) is a passive immunotherapy developed by the University of Health Sciences Lahore for the treatment of COVID-19. It consists of concentrated immunoglobulins (antibodies) purified from the blood serum of donors who have recovered from SARS-CoV-2 infection. By providing immediate, exogenous neutralizing antibodies, the therapy aims to reduce viral load and prevent disease progression in hospitalized patients with mild to moderately severe COVID-19. This approach serves as a stopgap measure to provide short-term immunity while the patient's own immune system develops a response, particularly for high-risk patients.
- Other names
- IVIG for COVID-19intravenous immunoglobulin therapyanti-SARS-CoV-2 IVIGanti-SARS-CoV2 IVIGanti-SARS-CoV 2 IVIG
02
Targets
M protein (SARS-CoV-2 membrane protein)SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)TMPRSS2 (Transmembrane protease serine 2)
Beyond the preview
Go deeper on anti-SARS-CoV-2 intravenous immunoglobulin (UHS Lahore).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-SARS-CoV-2 intravenous immunoglobulin (UHS Lahore).